EXL01

EXL01 in the Maintenance of Steroid-induced Clinical Response/Remission in Participants With Mild to Moderate Crohn's Disease

Evaluation of EXL01 a new Live Biotherapeutic Product to prevent recurrence of Clostridioides difficile infection in high-risk patients. LIVEDIFF

Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk Patients

EXL-01 in combination with nivolumab for advanced NSCLC refractory to immunotherapy'

EXL01 in Combination With Nivolumab for Advanced NSCLC Refractory to Immunotherapy.

Gut microbiome intervention with EXL01 in combination with nivolumab and FOLFOX as first-line treatment for patients with PD-L1 CPS ≥5 metastatic gastric cancer: A randomized GERCOR phase II study (BIG)

First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer

MICROBIOTA MODIFICATION FOR IMMUNO-ONCOLOGY IN HEPATOCELLULAR CARCINOMA - “MOTHER”

Microbiota Modification for Immuno-oncology in Hepatocellular Carcinoma

A Phase 2 multicentre, randomised, parallel-arm, placebo-controlled, double-blind study to evaluate the safety and target engagement of EXL01 in the prevention of post-operative recurrence of Crohn’s Disease